RHEUMATOLOGICAL ASPECTS AND TREATMENTS OF COVID-19: Edited by Rebecca H. HabermanThe role of immunomodulatory medications in the treatment of COVID-19Sattui, Sebastian E.a; Crow, Mary K.a; Navarro-Millán, Irisa,bAuthor Information aDivision of Rheumatology, Department of Medicine, Hospital for Special Surgery bDivision of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York, USA Correspondence to Iris Navarro-Millán, MD, MSPH, Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, 420 E 70th St., LH-363, New York, NY 10021, USA. E-mail: [email protected] Current Opinion in Rheumatology: September 2021 - Volume 33 - Issue 5 - p 431-445 doi: 10.1097/BOR.0000000000000817 Buy Metrics Abstract Purpose of review Given the role of inflammation in severe forms of COVID-19, glucocorticoids and disease-modifying antirheumatic drugs (DMARDs) have been assessed as potential COVID-19 therapies. Recent findings Randomized controlled trials (RCTs) have shown that glucocorticoids reduce mortality in severe COVID-19. RCTs of DMARDs have shown mixed results varying on intervention and inclusion criteria. DMARDs, including colchicine or biologic agents, may improve COVID-19 outcomes in specific patient populations. Summary Glucocorticoids are an effective treatment for the management of severe COVID-19. Further studies are needed to better define the patient populations who could benefit from DMARD use, as well as provide guidance regarding the timing of these interventions. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.